Bridger Management Has Increased Atara Biotherapeutics (ATRA) Holding; Carret Asset Management Has Lifted Its Sysco (SYY) Stake

November 15, 2017 - By Maria Brooks

Bridger Management Llc increased Atara Biotherapeutics Inc (ATRA) stake by 8.18% reported in 2017Q2 SEC filing. Bridger Management Llc acquired 115,286 shares as Atara Biotherapeutics Inc (ATRA)’s stock declined 2.88%. The Bridger Management Llc holds 1.52 million shares with $21.34M value, up from 1.41 million last quarter. Atara Biotherapeutics Inc now has $408.45M valuation. The stock declined 2.20% or $0.3 reaching $13.35 on the news. About 1,891 shares traded. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 7.28% since November 15, 2016 and is downtrending. It has underperformed by 23.98% the S&P500.

Carret Asset Management Llc increased Sysco Corp (SYY) stake by 28.15% reported in 2017Q2 SEC filing. Carret Asset Management Llc acquired 6,900 shares as Sysco Corp (SYY)’s stock rose 4.26%. The Carret Asset Management Llc holds 31,410 shares with $1.58 million value, up from 24,510 last quarter. Sysco Corp now has $28.42B valuation. The stock declined 0.71% or $0.39 reaching $54.55 on the news. About 29,863 shares traded. SYSCO Corporation (NYSE:SYY) has risen 11.23% since November 15, 2016 and is uptrending. It has underperformed by 5.47% the S&P500.




Among 19 analysts covering Sysco Corporation (NYSE:SYY), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. Sysco Corporation had 47 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of SYSCO Corporation (NYSE:SYY) earned “Neutral” rating by Goldman Sachs on Friday, December 9. The company was initiated on Tuesday, December 15 by Goldman Sachs. Credit Suisse downgraded the shares of SYY in report on Wednesday, November 16 to “Neutral” rating. As per Friday, March 11, the company rating was upgraded by Clevland Research. The firm earned “Outperform” rating on Friday, May 5 by BMO Capital Markets. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, August 3 report. The company was maintained on Monday, October 30 by Jefferies. The company was initiated on Friday, September 23 by Barclays Capital. The rating was initiated by Wells Fargo with “Outperform” on Thursday, November 19. The company was initiated on Monday, June 20 by Bank of America.

Since May 17, 2017, it had 0 insider buys, and 3 insider sales for $3.38 million activity. Another trade for 30,000 shares valued at $1.67M was sold by DeLaney William J III. Shurts Wayne had sold 15,600 shares worth $862,914 on Monday, June 12.

Investors sentiment increased to 0.87 in Q2 2017. Its up 0.08, from 0.79 in 2017Q1. It improved, as 44 investors sold SYY shares while 351 reduced holdings. 84 funds opened positions while 258 raised stakes. 414.66 million shares or 0.17% more from 413.94 million shares in 2017Q1 were reported. Signaturefd Limited holds 0.03% in SYSCO Corporation (NYSE:SYY) or 4,312 shares. Moreover, Ftb Advsrs Inc has 0% invested in SYSCO Corporation (NYSE:SYY) for 741 shares. Breton Hill Capital invested in 0.19% or 19,726 shares. Tradewinds Cap Mgmt Lc holds 766 shares. Lowe Brockenbrough Communications accumulated 71,039 shares or 0.56% of the stock. 7,800 were reported by Winfield Associates. Moreover, Endurance Wealth Mngmt Inc has 0.02% invested in SYSCO Corporation (NYSE:SYY) for 2,800 shares. Cornerstone Cap Hldgs Limited Liability reported 0.05% stake. Supplemental Annuity Collective Of Nj accumulated 17,029 shares. Geneva Advisors Lc owns 9,640 shares. Moreover, Shamrock Asset Mgmt Limited Liability Company has 0.13% invested in SYSCO Corporation (NYSE:SYY). Tompkins has invested 0.04% in SYSCO Corporation (NYSE:SYY). Victory Cap holds 2.92M shares. Moreover, Richard C Young & Ltd has 1.99% invested in SYSCO Corporation (NYSE:SYY). Oregon Pub Employees Retirement Fund has invested 0.05% in SYSCO Corporation (NYSE:SYY).

Investors sentiment decreased to 1.28 in Q2 2017. Its down 0.72, from 2 in 2017Q1. It worsened, as 14 investors sold ATRA shares while 18 reduced holdings. 14 funds opened positions while 27 raised stakes. 25.27 million shares or 6.68% more from 23.69 million shares in 2017Q1 were reported. Creative Planning holds 0% or 9,957 shares. Geode Mgmt Ltd Limited Liability Company reported 188,425 shares. 13,319 were accumulated by Credit Suisse Ag. Amer Intll Grp Inc Incorporated Inc invested in 15,803 shares or 0% of the stock. 2,602 were accumulated by Bnp Paribas Arbitrage. State Board Of Administration Of Florida Retirement Systems owns 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 10,253 shares. Hudson Bay Management Limited Partnership reported 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Dekabank Deutsche Girozentrale, a Germany-based fund reported 9,200 shares. Citigroup holds 0% or 169 shares in its portfolio. Art Advsrs Ltd Limited Liability Company invested in 0.01% or 18,438 shares. Invesco has 17,903 shares for 0% of their portfolio. Tiaa Cref Inv Limited Company holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 67,892 shares. Blackrock has 1.92M shares. Citadel Advsrs holds 36,462 shares or 0% of its portfolio. Artal stated it has 0.12% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA).

Bridger Management Llc decreased Humana Inc (NYSE:HUM) stake by 60,572 shares to 214,336 valued at $51.57 million in 2017Q2. It also reduced Wright Med Group N V stake by 740,180 shares and now owns 1.92 million shares. Mgm Resorts International (NYSE:MGM) was reduced too.

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 2 Sell and 0 Hold. Therefore 67% are positive. Atara Biotherapeutics had 16 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Buy” rating by Canaccord Genuity on Wednesday, September 9. The firm earned “Buy” rating on Monday, October 24 by Jefferies. The rating was reinitiated by Jefferies with “Buy” on Thursday, June 22. The firm earned “Market Outperform” rating on Tuesday, December 15 by JMP Securities. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Buy” rating given on Thursday, August 31 by Jefferies. The firm has “Sell” rating given on Monday, August 22 by Citigroup. The stock has “Sell” rating by Citigroup on Tuesday, December 15. Citigroup maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) rating on Friday, August 19. Citigroup has “Sell” rating and $8 target. Goldman Sachs initiated Atara Biotherapeutics Inc (NASDAQ:ATRA) on Wednesday, November 18 with “Neutral” rating. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Outperform” rating given on Friday, October 9 by William Blair.

Since May 17, 2017, it had 0 insider purchases, and 3 sales for $181,165 activity. Gallagher Carol Giltner sold $13,150 worth of stock or 1,000 shares. 6,900 shares were sold by Ciechanover Isaac E., worth $92,115. 6,000 shares were sold by Haqq Christopher, worth $75,900.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts